Davis G. Eric's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 1,273 Common Stock done at an average price of $56.1 . Disclosure was reported to the exchange on March 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.05 per share. | 18 Mar 2026 | 1,273 | 78,560 (0%) | 0% | 56.1 | 71,352 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2026 | 34,690 | 34,690 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2026 | 14,570 | 79,833 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.51 per share. | 16 Mar 2026 | 7,177 | 65,263 (0%) | 0% | 58.5 | 419,926 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 30,020 | 30,020 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.44 per share. | 14 Mar 2025 | 16,249 | 69,975 (0%) | 0% | 69.4 | 1,128,331 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 12,940 | 82,915 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 11,040 | 67,197 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 9,660 | 76,857 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 9,367 | 86,224 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 40,850 | 0 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.10 per share. | 28 May 2024 | 40,850 | 97,007 (0%) | 0% | 63.1 | 2,577,635 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 74.45 per share. | 28 May 2024 | 38,071 | 58,936 (0%) | 0% | 74.5 | 2,834,576 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 75.29 per share. | 28 May 2024 | 2,779 | 56,157 (0%) | 0% | 75.3 | 209,225 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2024 | 1,850 | 40,850 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 85.01 per share. | 02 May 2024 | 1,850 | 56,157 (0%) | 0% | 85.0 | 157,269 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.10 per share. | 02 May 2024 | 1,850 | 58,007 (0%) | 0% | 63.1 | 116,735 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 68.64 per share. | 02 May 2024 | 301 | 56,157 (0%) | 0% | 68.6 | 20,662 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 88.34 per share. | 28 Mar 2024 | 24,602 | 55,856 (0%) | 0% | 88.3 | 2,173,341 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 22,990 | 22,990 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.87 per share. | 15 Mar 2024 | 21,699 | 80,458 (0%) | 0% | 83.9 | 1,819,895 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 10,260 | 102,157 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Eric Davis G. | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 20,840 | 76,550 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Eric Davis G. | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 9,063 | 85,613 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Eric G. Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 6,284 | 91,897 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Davis G. Eric | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 95.30 per share. | 13 Dec 2023 | 13,764 | 55,710 (0%) | 0% | 95.3 | 1,311,709 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 89.42 per share. | 08 Aug 2023 | 11,000 | 69,474 (0%) | 0% | 89.4 | 983,662 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 66.88 per share. | 28 Apr 2023 | 317 | 80,684 (0%) | 0% | 66.9 | 21,201 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Apr 2023 | 210 | 80,474 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 20,320 | 20,320 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.41 per share. | 15 Mar 2023 | 19,957 | 80,367 (0%) | 0% | 93.4 | 1,864,183 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 8,900 | 103,349 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.74 per share. | 15 Mar 2023 | 3,025 | 100,324 (0%) | 0% | 87.7 | 265,414 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 20,200 | 76,925 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 10,100 | 87,025 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 7,424 | 94,449 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2023 | 1,474 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 24 Feb 2023 | 1,474 | 56,725 (0%) | 0% | 67.8 | 99,952 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 47,526 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 95.93 per share. | 09 Aug 2022 | 47,526 | 55,251 (0%) | 0% | 95.9 | 4,559,169 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 09 Aug 2022 | 47,526 | 102,777 (0%) | 0% | 67.8 | 3,222,738 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 96.34 per share. | 09 Aug 2022 | 3,690 | 55,251 (0%) | 0% | 96.3 | 355,495 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 08 Jul 2022 | 7,398 | 58,941 (0%) | 0% | 90 | 665,820 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 80.38 per share. | 29 Apr 2022 | 15,347 | 66,339 (0%) | 0% | 80.4 | 1,233,592 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.46 per share. | 29 Apr 2022 | 15,347 | 81,686 (0%) | 0% | 37.5 | 574,899 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2022 | 15,347 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 29 Apr 2022 | 341 | 66,339 (0%) | 0% | 62.4 | 21,281 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.46 per share. | 25 Apr 2022 | 2,669 | 65,998 (0%) | 0% | 37.5 | 99,981 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 2,669 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 81.29 per share. | 21 Mar 2022 | 6,129 | 63,329 (0%) | 0% | 81.3 | 498,226 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 26,520 | 26,520 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 11,040 | 79,000 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.27 per share. | 15 Mar 2022 | 8,290 | 70,710 (0%) | 0% | 78.3 | 648,858 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.72 per share. | 15 Mar 2022 | 1,252 | 69,458 (0%) | 0% | 80.7 | 101,061 | Common Stock |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 9,370 | 67,960 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | G. Eric Davis | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 76.69 per share. | 02 Aug 2021 | 5,518 | 58,590 (0%) | 0% | 76.7 | 423,175 | Common Stock |